Wall Street analysts just called this healthcare stock a buy — here’s our take
Every weekday, the CNBC Investing Club with Jim Cramer holds a “Morning Meeting” livestream at 10:20 a.m. ET.…
Safety and security of large language models in healthcare
Gommers, J. et al. Interval cancer, sensitivity, and specificity comparing AI-supported mammography screening with standard double reading without…
Cuba has plenty of doctors. So why is its healthcare system collapsing?
Since January, many Cubans have lived a life of near-constant darkness. The Trump administration’s oil blockades have led…
CareCloud confirms 3.7M patients had their medical records stolen in data breach
Hackers have stolen the personal information and medical records of more than 3.75 million people in a data…
The Exec’s Guide to Longevity Tech
Then, alongside the launch of Oura Ring 5 in June 2026, Oura introduced a suite of software features…
Are you an Australian living with dementia? We’d like to hear from you | Health
Dementia deaths more than doubled in Australia in the 15 years between 2009 and 2024, the latest available…
Healthcare results wrap: Are Cogstate and Pro Medicus shares a buy, hold or sell?
Yesterday, both Cogstate Ltd (ASX: CGS) and Pro Medicus Ltd (ASX: PME) released FY26 results. Investors reacted very…
Health Check: More ASX healthcare winners emerge from the reporting fiesta
Spelling bee whizzes: EBOS and Alcidion are today’s reporting champs, for spelling out ‘enhanced shareholder satiation amid exogenous…
Man tries ‘shocking’ ADHD drug as he questions if disorder is ‘genuine’ or social construct
An NHS psychiatrist tried ADHD medication that an expert compared to ‘slow release cocaine’ after being diagnosed with…
Gilead Sciences Has Quietly Become One of the Most Underrated Turnaround Stories in Healthcare. Here’s Why Wall Street Is Excited.
Gilead Sciences (GILD +3.25%) has shifted from a period of stagnant growth, driven by slowing hepatitis C revenues…
Johnson & Johnson Stock Jumps 3% as Healthcare Rotation Lifts Shares
This article first appeared on GuruFocus. Johnson & Johnson (NYSE:JNJ), the healthcare heavyweight behind blockbuster medicines and medical…
Scoop: Johnson & Johnson to Lead Delix Therapeutics’ $85M Series C
Delix Therapeutics was the first well-funded ‘non-hallucinogenic psychedelic’ drug developer to emerge, in many ways defining the category.…